Stockscreener 앱 받기
25.88
3.11%
-0.83
시간 외 거래:
26.45
0.57
+2.20%
전일 마감가:
$26.71
열려 있는:
$26.15
하루 거래량:
188.86K
Relative Volume:
0.35
시가총액:
$358.56M
수익:
-
순이익/손실:
$-19.48M
주가수익비율:
-17.68
EPS:
-1.4641
순현금흐름:
$-8.59M
1주 성능:
-2.49%
1개월 성능:
+3.81%
6개월 성능:
+125.83%
1년 성능:
+126.03%
1일 변동 폭
$24.61
$26.49
1주일 범위
$24.61
$30.25
52주 변동 폭
$7.78
$34.10
그리니치 Stock (GLSI) Company Profile
명칭
Greenwich Lifesciences Inc
전화
203-434-3290
주소
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
25.88 | 370.05M | 0 | -19.48M | -8.59M | -1.4641 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
그리니치 Stock (GLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-20 | 개시 | Noble Capital Markets | Outperform |
| 2021-09-01 | 개시 | H.C. Wainwright | Buy |
그리니치 주식(GLSI)의 최신 뉴스
Greenwich LifeSciences Inc initiates new US clinical sites for Flamingo-01 phase III trial - marketscreener.com
Greenwich LifeSciences expands Phase III trial to City of Hope sites - Investing.com
Greenwich LifeSciences, Inc. Announces Addition of City of Hope to Flamingo-01 - marketscreener.com
City of Hope joins breast cancer trial, widening access across US sites - Stock Titan
Liquidity Mapping Around (GLSI) Price Events - Stock Traders Daily
Greenwich LifeSciences to present trial data at AACR meeting By Investing.com - Investing.com Canada
Greenwich LifeSciences to present trial data at AACR meeting - Investing.com
Greenwich Lifesciences provides update on upcoming AACR meeting - marketscreener.com
Greenwich Lifesciences Provides Update On Upcoming Aacr Meeting - TradingView
Greenwich LifeSciences, Inc. Announces Presentation of FLAMINGO-01 Phase III Clinical Trial Data at AACR Meeting 2026 - Quiver Quantitative
Greenwich LifeSciences to share AACR Meeting plans - Traders Union
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting - GlobeNewswire Inc.
Why is GLSI stock rising today? - MSN
Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer. - Bitget
Why Is GLSI Stock Rising Today? - Mena FN
Greenwich LifeSciences reports reduced cancer recurrence in trial - Investing.com
Greenwich LifeSciences provides update showing continued reduction in recurrence rate in the open label arm of Flamingo-01 - marketscreener.com
Greenwich Lifesciences Provides Update Showing Continued Reduction In Recurrence Rate In The Open Label Arm Of Flamingo-01 - TradingView
Greenwich LifeSciences reports reduced cancer recurrence in trial By Investing.com - Investing.com UK
Breast cancer trial sees under 1% yearly recurrences in GLSI-100 arm - Stock Titan
Greenwich LifeSciences begins using commercial GP2 at US sites By Investing.com - Investing.com South Africa
Greenwich LifeSciences begins using commercial GP2 at US sites - Investing.com
Greenwich LifeSciences Provides Update on Phase III Clinical Trial FLAMINGO-01 and Commercial Manufacturing of GP2 - Quiver Quantitative
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 - Sahm
Big Money Moves: Is Greenwich LifeSciences Inc undervalued by DCF analysisPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% – Should You Buy? - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6%Should You Buy? - MarketBeat
Why (GLSI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
ETF Watch: Is Greenwich LifeSciences Inc a turnaround storyWeekly Investment Recap & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Market Review: Is Greenwich LifeSciences Inc a stock for growth or value investorsMarket Activity Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
GLSI Should I Buy - Intellectia AI
Noble Financial Sticks to Their Buy Rating for Greenwich LifeSciences (GLSI) - The Globe and Mail
Greenwich LifeSciences reports 33% rise in trial screening rate By Investing.com - Investing.com Canada
Greenwich LifeSciences reports 33% rise in trial screening rate - Investing.com South Africa
Greenwich LifeSciences accelerates patient screening in FLAMINGO-01 clinical trial - Traders Union
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 - GlobeNewswire
US Stocks Recap: Is Greenwich LifeSciences Inc undervalued by DCF analysisTrade Exit Summary & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Aug Sentiment: Can Greenwich LifeSciences Inc expand into new marketsOptions Play & Long-Term Safe Investment Ideas - baoquankhu1.vn
GLSI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Understanding Momentum Shifts in (GLSI) - Stock Traders Daily
Greenwich LifeSciences abstracts accepted at AACR 2026 meeting By Investing.com - Investing.com Australia
Greenwich LifeSciences abstracts accepted at AACR 2026 meeting - Investing.com Nigeria
Rally Mode: Is BTCM a cyclical or defensive stockWall Street Watch & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Greenwich lands 2 AACR 2026 slots, first with FLAMINGO-01 Steering Committee - Stock Titan
GLSI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 - ChartMill
Analysis Recap: Is SPRY stock showing strong momentumQuarterly Market Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Down 14.7% in January - MarketBeat
How interest rate cuts could boost Greenwich LifeSciences Inc. stockJuly 2025 Macro Moves & Consistent Return Investment Signals - mfd.ru
GLSI PE Ratio & Valuation, Is GLSI Overvalued - Intellectia AI
그리니치 (GLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):